Key result
The genetically encoded fluorescent voltage indicator ArcLight can faithfully report transmembrane potentials in human stem cell-derived cardiomyocytes for high-throughput phenotyping and drug screening.
Population
human pluripotent stem cell-derived cardiomyocytes
Design
Preclinical
Authors
Loading...
No immediate change to clinical cardiotoxicity assessment; leaves open validation of stem cell models for arrhythmia screening.
The ArcLight fluorescent voltage sensor provides a non-phototoxic, high-throughput method for electrophysiological phenotyping and cardiotoxicity screening in human stem cell-derived cardiomyocytes.
Leyton‐Mange et al. (2014) studied Cardiac arrhythmia syndromes. Genetically encoded fluorescent voltage indicator (ArcLight) was evaluated on Reporting of transmembrane potentials, serial phenotyping, and screening for drug-induced cardiotoxicity. The genetically encoded fluorescent voltage indicator ArcLight can faithfully report transmembrane potentials in human stem cell-derived cardiomyocytes for high-throughput phenotyping and drug screening.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: